Moleculin's Annamycin Shows Early Promise in AML Trial, Awaits Unblinding
Event summary
- Moleculin expects to unblind initial data from its MIRACLE trial before June 30, 2026, showing a preliminary blinded CR rate of ~30% in 45 subjects, a 67% improvement over historical benchmarks.
- The trial targets relapsed/refractory AML patients, including those resistant to venetoclax, with 30% of subjects in this challenging cohort.
- Recruitment for Part A of the trial is on track to reach 90 subjects by Q3 2026, with 56 subjects already enrolled as of May 13, 2026.
- Annamycin has Fast Track and Orphan Drug Designations from the FDA and EMA, with patent protection extending to 2040 (potentially 2045).
The big picture
Moleculin's Annamycin is positioned as a potential breakthrough in treating relapsed/refractory AML, a high-unmet-need population. The trial's adaptive design and early efficacy signals could accelerate its path to market, though competition and financing remain critical factors. The absence of cardiotoxicity in Annamycin may give it a safety advantage over existing anthracyclines.
What we're watching
- Trial Efficacy
- How the unblinded data will compare to historical benchmarks and whether the 30% CR rate holds up.
- Regulatory Pathway
- Whether the MIRACLE trial results will support a potential FDA approval for Annamycin in AML.
- Market Positioning
- The pace at which Annamycin can differentiate itself from existing AML treatments, particularly in venetoclax-resistant patients.